Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

/b>

Carfilzomib is the first in a new class of selective, irreversible proteasome inhibitors. Carfilzomib produces specific and sustained inhibition of the proteasome, leading to apoptosis in cancer cells with minimal off-target effects. In Phase 1 and Phase 2 clinical trials, carfilzomib has demonstrated single-agent activity in hematologic malignancies and solid tumors, including multiple myeloma, Waldenstrom's macroglobulinemia, mantle cell lymphoma and renal cell carcinoma.

Proteolix is conducting a comprehensive clinical development program evaluating carfilzomib for the treatment of multiple myeloma, including an ongoing accelerated approval study in heavily pre-treated relapsed/refractory patients and a Phase 2 clinical trial in relapsed patients stratified by prior treatment with bortezomib. Both Phase 2 clinical trials are being conducted by Proteolix in collaboration with the Multiple Myeloma Research Consortium (MMRC). A Phase Ib clinical trial of carfilzomib in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma is also ongoing. In addition, Proteolix is conducting a single-agent Phase 2 clinical trial of carfilzomib in patients with recurrent or advanced solid tumors. For the latest information regarding ongoing carfilzomib clinical trials, please visit www.clinicaltrials.gov.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biotechnology company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of selective, irreversible proteasome inhibitors. Proteolix is also developing a pipeline of novel proteasome inhibitors, including a selective, oral proteaso
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Pittcon is pleased to announce that the 2015 ... Scientific, have organized a session on nanotechnology for presentation ... Asia’s largest analytical and scientific instruments show, will be ... , The four speakers in this U.S. symposium, “Thinking ... Single Cells” will present their use of nanotechnology to ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... Surgeons directory service and website at www.TrustedLASIKSurgeons.com ... their vision and find a highly qualified LASIK surgeon. ... is a unique screening process ensuring that only those ... and laser eye surgery in the United States are ...
... Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) has announced ... and high-risk research projects. The Joint Committee of ... has approved funding for two new Reinhart Koselleck ... and Professor Reinhard Drner, an atomic physicist from ...
... animals have been our first line of defense against toxins. ... monitor for poisonous gases. Scientists used fish to test ... though, it can take days to detect a fatal chemical ... miniaturized world of nanotechnology, Tel Aviv University researchers have made ...
Cached Biology Technology:Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 2Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 3Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 4Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 5Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 6Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 7Dr. Lawrence Spivack, a LASIK Eye Surgeon Expert Serving Denver, Colorado, Joins Elite Circle of Surgeons Listed at Trusted LASIK Surgeons 8Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects 2Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects 3Tiny 'lab-on-a-chip' detects pollutants, disease and biological weapons 2
(Date:9/1/2014)... 10:20 AM EDT) It may be possible to ... unhealthy higher-calorie foods, according to new research by scientists ... on Aging (USDA HNRCA) at Tufts University and at ... Nutrition & Diabetes , a brain scan study ... possible to reverse the addictive power of unhealthy food ...
(Date:9/1/2014)... animals, bats are perfectly adapted to a life without light. ... reflected echoes to measure distance to obstacles or prey. In ... delays. A study carried out by researchers at Technische Universitt ... map dynamically adapts to external factors. , Closer ... in too close to an object, the number of activated ...
(Date:8/31/2014)... new blood test provides a fast and accurate ... proof-of-concept study shows. The newly developed test (TAM-TB ... detect active tuberculosis in children. The test features ... in combination with speed of a blood test. ... the diagnosis of tuberculosis in children, particularly in ...
Breaking Biology News(10 mins):Training your brain to prefer healthy foods 2Zooming in for a safe flight 2New tuberculosis blood test in children is reliable and highly specific 2
... awarded to enhance the development of biopharmaceuticals. , In ... important results, such as industrial-scale production of antibodies, stem ... and commercial scale stem cell therapy. , The ... 2 of the Bioprocessing Research Industry Club (BRIC), a ...
... where a pathogen is transmitted between two individuals in ... a disease will spread. New research has laid ... spreading models, which could allow for more targeted prevention ... study, published in Physical Review Letters , outlines ...
... Calif. , Feb. 5, 2013 DigitalPersona, Inc., ... announced that the DigitalPersona ® Eikon ® Touch ... ® 4500 Reader UID edition USB based single ... and Quality Certification (STQC) Directorate, an office of the ...
Cached Biology News:£6.5M in funding to help manufacture the drugs of the future 2£6.5M in funding to help manufacture the drugs of the future 3£6.5M in funding to help manufacture the drugs of the future 4£6.5M in funding to help manufacture the drugs of the future 5Can you predict how a disease will spread in a population? 2DigitalPersona Fingerprint Readers Receive STQC Certification for UIDAI Program in India 2DigitalPersona Fingerprint Readers Receive STQC Certification for UIDAI Program in India 3
Pim-1 (12H8)...
Ets-1...
Mouse monoclonal [3G131] to Desmoglein 1 ( Abpromise for all tested applications). entrezGeneID: 1828 SwissProtID: Q02413...
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
Biology Products: